Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
The collaboration will leverage Orbit’s expertise and bead-based peptide display engine for the identification, screening, and selection of cyclic peptides specific to a wide range of disease targets, to be paired with Secarna’s ASO molecules. The addition of cyclic peptides to Secarna’s proprietary ASO discovery and development platform will expand its therapeutic spectrum, positioning it to develop targeted antisense assets beyond modalities such as antibodies and sugar molecules, like GalNAc. We are very pleased to embark on this collaboration with Orbit Discovery, as the team’s expertise in peptide discovery and development will further enhance our capabilities for the development of targeted antisense therapeutics Konstantin Petropoulos, CBO, Secarna Pharmaceuticals.
“We look forward to working with Orbit to expand both the therapeutic potential and universe of targeted ASO therapeutics with highly specific, potent, safe and convenient therapeutic options available for patients who urgently need them.” Orbit’s peptide discovery services enable the screening of large libraries of peptides.
